MONTREAL,
Oct. 10, 2014 /PRNewswire/ - Bioniche
Life Sciences Inc. (TSX: BNC: PNK:BNHLF) today announced that The
Journal of Urology has accepted for publication a manuscript
entitled: Efficacy and Safety of MCNA in Patients with
Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and
Progression Who Have Failed Treatment with
Bacillus Calmette-Guérin. An unedited version of the
paper is now available for review and citation online at
www.jurology.com
(http://www.jurology.com/article/S0022-5347(14)04590-X/abstract);
with an expected in print date tentatively scheduled for
April 2015.
The data reported in this publication pertains to pivotal Phase
3 study conducted with MCNA (Mycobacterium phlei cell wall-nucleic
acid complex) and includes results of planned statistical analyses
at study completion including efficacy rates at 3 and 6 months and
2 years after therapy. Post-hoc analyses were performed to
determine the efficacy of MCNA in subgroups of
bacillus Calmette-Guérin (BCG)-failure patients and outcomes
of treatment such as duration of response, impact on progression
and cystectomy rates are also presented. These analyses complement
the previous interim study results that appeared in abstract form
which were presented at North American and international urology
conferences.
Commenting on this publication, Bioniche's CEO & Chief
Scientist, Dr. Michael Berendt
declared: "We are very excited to be able to report to the global
urology community, for the first time, a comprehensive dataset from
our pivotal Phase 3 study that will serve as the foundation of our
upcoming Biologics License Application (BLA) filing. We
continue to believe that our lead product, MCNA, addresses a real
unmet medical need in this poorly served, high-risk population who
have failed the current standard of care, BCG treatment, and who
seek non-surgical treatment alternatives to prevent or delay
cystectomy.
The article's corresponding author and a
Principal Investigator in the MCNA pivotal Phase 3 study, Dr.
Ashish M. Kamat, a Professor and
Attending Surgeon in the Department of Urology/Division of Surgery
and Director of the Urologic Oncology Fellowship Program at The
University of Texas MD Anderson Cancer Center commented:
"Intravesical MCNA offers an alternative for patients who have
failed therapy with BCG and do not wish to undergo a radical
cystectomy. Since it's mechanism of action is based on a
combination of immunologic and direct cytotoxic principles, it has
the potential to establish durable response as well."
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a late clinical
stage Canadian biopharmaceutical company focused on the
development, manufacturing, marketing and licensing/acquisition of
proprietary and innovative therapies for the global human health
market. The Company's primary goal is to develop and commercialize
products that advance human health and increase shareholder value.
For more information, please visit www.Bioniche.com.
Except for historical information, this news
release may contain "forward-looking statements" and
"forward-looking information" within the meaning of applicable
securities laws that reflect the Company's current expectation
regarding future events, including, without limitation, the
proposed use of proceeds and the timing and completion of the
Offering. Forward-looking statements and information are
necessarily based upon a number of estimates and assumptions that,
while, considered reasonable by management, are inherently subject
to significant business, economic and competitive uncertainties and
contingencies. Readers are cautioned that any such forward-looking
statements and information are not guarantees and there can be no
assurance that such statements and information will prove to be
accurate, and actual results and future events could differ
materially from those anticipated in such statements and
information. These forward-looking statements and information
involve risk and uncertainties, which may cause, but are not
limited to, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. The Company
expressly disclaims any intention or obligation to update or revise
any forward-looking statements and information whether as a result
of new information, future events or otherwise. All written and
oral forward-looking statements and information attributable to us
or persons acting on our behalf are expressly qualified in their
entirety by the foregoing cautionary statements.
SOURCE Bioniche Life Sciences Inc.
